Temperature-dependent drug may prevent blood clots during therapeutic hypothermia

April 9, 2010

To prevent blood clots during therapeutic hypothermia, scientists have developed what may be the first drug activated by cool temperatures and turned off by warm ones, according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2010.

"We used biotechnology to create a modern intelligent drug," said Karlheinz Peter, M.D., Ph.D., leading author of the study and associate director of Baker IDI Heart & Diabetes Institute in Melbourne, Australia. "This drug is tailored for preventing clots during and for minimizing bleeding problems especially after rewarming."

Doctors use therapeutic hypothermia when the heart temporarily stops beating either spontaneously (cardiac arrest) or during cardiovascular surgery. In this procedure, doctors lower a patient's internal body temperature to prevent organ injury, including brain damage, by reducing metabolic rate and oxygen requirements.

The new drug works only at cooler temperatures by inhibiting the activity of platelets, which are cells that bind together to stop bleeding. In mouse and human blood samples, researchers demonstrated that the experimental drug bound to platelets and prevented them from clumping together at cool temperatures (22º C or 71.6º F). When the researchers raised the temperature to normal (37º C or 98.6º F), the anti-platelet action stopped.

"Our idea was to develop a reagent that is highly active at the moment it is really needed ─ when patients are at low temperature ─ and that loses its function when it is no longer needed ─ when patients are rewarmed," Peter said.

Peter and his collaborators at Baker and Emory University in Atlanta, Ga., used recombinant DNA technology to fuse a temperature-dependent protein with a protein that inhibits platelet activity. The first part of this new protein is similar to the protein elastin, which gives skin and other organs their flexibility and is known to change shape in response to temperature changes. The second, antibody portion of this combined protein inhibits platelet activity by blocking the receptors that normally enable these cells to clot together to heal an injury.

For centuries, physicians have recognized therapeutic hypothermia's benefits, but its use in cardiac patients is relatively recent. In the 1950s, doctors began using the treatment for cardiac surgery, such as valve and bypass surgery. Also, hypothermia is often used in surgical repair of structural cardiac defects in infants and children. However, cardiac hypothermic surgery is associated with a substantial risk of clotting.

To prevent this serious complication, anti-clotting medication is a standard part of therapeutic hypothermia. The drawback is that the effects of current anti-clotting medicines continue even after body temperature is raised to a normal level, which sometimes leads to excessive post-surgical bleeding, researchers said. In contrast, the new combined protein not only inhibited blood clot formation during cooling but also prevented bleeding problems after rewarming.

After extensive clinical studies, the American Heart Association in October 2002 recommended that therapeutic hypothermia also be used to treat selected patients who have suffered cardiac arrest. Using cooling blankets, ice packs or other methods, doctors lower a patient's internal body temperature for 12 to 24 hours. This highly effective therapy can increase survival rate and decrease long-term disability, but it can sometimes cause .

To assure that the novel temperature-dependent drug also protects patients subjected to this type of therapeutic hypothermia used for the protection of the brain in patients after cardiocirculatory arrest, further studies are needed to determine the extent of platelet inhibition at temperatures such as 32º C to 34ºC (89.6 º F to 93.2 º F), Peter said.

Explore further: Lowering body temperature could aid standard stroke treatment

Related Stories

Lowering body temperature could aid standard stroke treatment

May 17, 2007

University of Cincinnati scientists have developed a model that could help physicians combine current clot-busting medication with below-normal body temperatures (hypothermia) to improve the treatment of ischemic stroke patients.

Post-cardiac arrest care key to survival

October 23, 2008

The urgent need for treatment doesn't end when a person regains a pulse after suffering sudden cardiac arrest — healthcare providers need to move quickly into post-cardiac arrest care to keep a person alive and ensure the ...

Cooling may benefit children after cardiac arrest

December 3, 2009

When the heart is stopped and restarted, the patient's life may be saved but their brain is often permanently damaged. Therapeutic hypothermia, a treatment in which the patient's body temperature is lowered and maintained ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.